-
Ferring Japan announces PMDA Acceptance of NDA Filing for nadofaragene firadenovec
in PRESS RELEASE 2025 on…
00 -
Ferring Pharmaceuticals announces results of the IRIS Study: A comparative analysis of individualised vs.conventional recombinant follicular stimulating hormone dosing in Indian infertile patients
in PRESS RELEASE 2025 onFerring Pharmaceuticals announces results of the IRIS Study: A comparative analysis of…
-
U.S. FDA approves second drug product manufacturing facility for Adstiladrin® (nadofaragene firadenovec-vncg)
in PRESS RELEASE 2025 onU.S. FDA approves second drug product manufacturing facility for Adstiladrin® (nadofaragene firadenovec-vncg)…
-
Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating 75% Complete Response Rate at 3 Months with (nadofaragene firadenovec) in BCG-unresponsive NMIBC patients
in PRESS RELEASE 2025 onFerring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating…
-
Ferring achieved record sales driven by Reproductive Medicine combined with the emergence of Adstiladrin
in PRESS RELEASE 2025 onFerring achieved record sales driven by Reproductive Medicine combined with the emergence…
PRESS RELEASE 2025
PRESS RELEASE 2025